|
| Issue Date | Title | Author(s) |
| 2009 | Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML | Zhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J.; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K. |
| 2009 | Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML | Zhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J. ; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K. |
| 2008 | In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor | Zhou, J. ; Khng, J.; Jasinghe, V.J.; Bi, C.; Poon, L.F.; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K. |
| 2008 | In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor | Zhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K. |
| 2008 | In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor | Zhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J. ; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K. |
| Jan-2008 | Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway | Zhou, J. ; Pan, M.; Xie, Z. ; Loh, S.-L.; Bi, C.; Tai, Y.-C.; Lilly, M.; Lim, Y.-P. ; Han, J.-H.; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.; Chen, C.-S. |
